Minodronic acid(Synonyms: YM-529)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Minodronic acid (Synonyms: YM-529) 纯度: ≥98.0%

Minodronic acid (YM-529) 是第三代二磷酸盐，直接或间接地阻止增殖，诱导细胞凋亡，并抑制各种类型的癌细胞的转移。Minodronic acid (YM-529) 是一种参与疼痛的嘌呤 P2X2/3 受体拮抗剂。

Minodronic acid(Synonyms: YM-529)

Minodronic acid Chemical Structure

CAS No. : 180064-38-4

规格 价格 是否有货 数量
10 mM * 1 mL in Water ￥550 In-stock
10 mg ￥500 In-stock
50 mg ￥1500 In-stock
100 mg ￥2500 In-stock
200 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

Minodronic acid 相关产品

•相关化合物库:

  • Drug Repurposing Compound Library Plus
  • Clinical Compound Library Plus
  • Bioactive Compound Library Plus
  • Apoptosis Compound Library
  • Membrane Transporter/Ion Channel Compound Library
  • Anti-Cancer Compound Library
  • Clinical Compound Library
  • Drug Repurposing Compound Library
  • Neurotransmitter Receptor Compound Library
  • Rare Diseases Drug Library

生物活性

Minodronic acid (YM-529) is a third-generation bisphosphonate that directly and indirectly prevents proliferation, induces apoptosis, and inhibits metastasis of various types of cancer cells. Minodronic acid (YM-529) is an antagonist of purinergic P2X2/3 receptors involved in pain[1][2].

IC50 & Target

P2X2/3[2]
Clinical Trial

分子量

322.15

Formula

C9H12N2O7P2
CAS 号

180064-38-4
中文名称

米诺磷酸
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

H2O : 5 mg/mL (15.52 mM; Need ultrasonic and warming)

DMSO : < 1 mg/mL (insoluble or slightly soluble)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 3.1041 mL 15.5207 mL 31.0414 mL
5 mM 0.6208 mL 3.1041 mL 6.2083 mL
10 mM 0.3104 mL 1.5521 mL 3.1041 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。
参考文献

  • [1]. Sato K, et al. A third-generation bisphosphonate, minodronic acid (YM529), successfully prevented the growth of bladder cancer in vitro and in vivo. Br J Cancer. 2006 Nov 20;95(10):1354-61.

    [2]. Tanaka M, et al. Minodronic acid induces morphological changes in osteoclasts at bone resorption sites and reaches a level required for antagonism of purinergic P2X2/3 receptors. J Bone Miner Metab. 2018 Jan;36(1):54-63.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务